222 related articles for article (PubMed ID: 18025536)
1. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
[TBL] [Abstract][Full Text] [Related]
2. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
3. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
[TBL] [Abstract][Full Text] [Related]
4. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
[TBL] [Abstract][Full Text] [Related]
5. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gilbert JC; Gorczyca ME; Knöbl P; Jilma B
Thromb Haemost; 2011 Sep; 106(3):539-47. PubMed ID: 21833442
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gorczyca ME; Jilma B; Siller-Matula J; Gilbert JC; Knöbl P
Thromb Haemost; 2011 Mar; 105(3):545-52. PubMed ID: 21174003
[TBL] [Abstract][Full Text] [Related]
7. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
Knöbl P; Jilma B; Gilbert JC; Hutabarat RM; Wagner PG; Jilma-Stohlawetz P
Transfusion; 2009 Oct; 49(10):2181-5. PubMed ID: 19538431
[TBL] [Abstract][Full Text] [Related]
8. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
Cosmi B
Curr Opin Mol Ther; 2009 Jun; 11(3):322-8. PubMed ID: 19479665
[TBL] [Abstract][Full Text] [Related]
9. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
[TBL] [Abstract][Full Text] [Related]
10. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis.
Arzamendi D; Dandachli F; Théorêt JF; Ducrocq G; Chan M; Mourad W; Gilbert JC; Schaub RG; Tanguay JF; Merhi Y
Clin Appl Thromb Hemost; 2011; 17(6):E70-8. PubMed ID: 21078615
[TBL] [Abstract][Full Text] [Related]
11. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial.
Markus HS; McCollum C; Imray C; Goulder MA; Gilbert J; King A
Stroke; 2011 Aug; 42(8):2149-53. PubMed ID: 21700934
[TBL] [Abstract][Full Text] [Related]
12. Targeting von Willebrand factor and platelet glycoprotein Ib receptor.
Firbas C; Siller-Matula JM; Jilma B
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1689-701. PubMed ID: 21108551
[TBL] [Abstract][Full Text] [Related]
13. Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets.
Chen 陈温纯 W; Voos KM; Josephson CD; Li R
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2028-2037. PubMed ID: 31315441
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
Diener JL; Daniel Lagassé HA; Duerschmied D; Merhi Y; Tanguay JF; Hutabarat R; Gilbert J; Wagner DD; Schaub R
J Thromb Haemost; 2009 Jul; 7(7):1155-62. PubMed ID: 19422452
[TBL] [Abstract][Full Text] [Related]
16. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
17. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
Bae ON
Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
[TBL] [Abstract][Full Text] [Related]
18. Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.
Sakai K; Someya T; Harada K; Yagi H; Matsui T; Matsumoto M
Haematologica; 2020 Nov; 105(11):2631-2638. PubMed ID: 33131252
[TBL] [Abstract][Full Text] [Related]
19. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
20. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
